Cargando…
Identification of Age-Associated Transcriptomic Changes Linked to Immunotherapy Response in Primary Melanoma
Melanoma is a lethal form of skin cancer. Immunotherapeutic agents such as anti-PD-1 (pembrolizumab and nivolumab) and anti-CTLA-4 (ipilimumab) have revolutionized melanoma treatment; however, drug resistance is rapidly acquired. Several studies have reported an increase in melanoma rates in older p...
Autores principales: | El-Helbawy, Nehal Farid, El Zowalaty, Ahmed Ezat |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9497511/ https://www.ncbi.nlm.nih.gov/pubmed/36135194 http://dx.doi.org/10.3390/cimb44090282 |
Ejemplares similares
-
The age of enlightenment in melanoma immunotherapy
por: Albertini, Mark R.
Publicado: (2018) -
Identification of Small Molecule Enhancers of Immunotherapy for Melanoma
por: Dextras, Christopher, et al.
Publicado: (2020) -
Combined Immunotherapy in Metastatic Melanoma with Unknown Primary
por: Khan, Yasir, et al.
Publicado: (2019) -
High-Dimensional Single-Cell Transcriptomics in Melanoma and Cancer Immunotherapy
por: Quek, Camelia, et al.
Publicado: (2021) -
A pretreatment transcriptomic signature that predicts outcomes of immunotherapy in melanoma
por: Hu, Junjie, et al.
Publicado: (2022)